Stanley et al. conducted a randomized, double-blinded, placebo-controlled trial that evaluated the effect of 12 months of therapy with growth hormone-releasing hormone (GHRH) analog (tesamorelin) in 61 patients affected by HIV and NAFLD. Here, GHRH is linked to metabolic dysfunction-associated steatotic liver disease.